摘要
目的探讨经皮胸腔内置管顺铂联合白介素2（interleukin-2，IL-2）治疗恶性胸腔积液的疗效。方法病理确诊为恶性胸腔积液72例，经皮胸腔内置管引流排尽胸液后，分治疗组37例予IL-2100万U，加生理盐水50ml，顺铂按80mg／m^2，加生理盐水40ml胸腔内注射，对照组35例患者采用顺铂80mg／m^2加生理盐水50ml胸腔内注射，注药后每周B超复查胸水情况，如胸水再积聚，则重复1次上述治疗。观察疗效、生活质量、生存率以及不良反应。结果治疗组总有效率为83．8％，高于对照组5＇4．3％，病变进展率8．1％，明显低于对照组25．7％，差异有统计学意义（P〈0．05）。Karnofsky评分大于70分治疗组疗效较对照组显著提高（P〈0．05）。治疗组6个月、12个月的生存率分别为92．0％、48．6％，分别高于对照组的62．9％、34．3％，其中6个月生存率差异有统计学意义（P〈0．05）。两组均有发热、恶心呕吐、外周自细胞减少等不良反应，但差异均无统计学意义。结论胸腔注入IL-2及顺铂治疗恶性胸腔积液是一种疗效肯定、经济安全的方法。
Objective To evaluate the efficacy of treating malignant pleural effusion with cisplatine and interleukin-2 by injection through thoracic tube intubation. Methods 72 cases with malignant pleural effusion,after drainage,interleukin-2 1 000 000 U, cisplatine 80 mg/m^2 were injected into pleural cavity in therapy group （n=37）,and only cisplatine 80 mg/m^2 in control group （n= 35）. The tretment was repeated after a week, then the efficacy, survival rate, toxicities and quality of life were evaluated. Results The responserate was 83.8% in therapy group and 54.3% in control group. The rate of disease pre gress was 8.1 % in therapy group and 25.7 % in control group. There was statistical difference between two groups （ P 〈0. 05）. Karnofsky score was higher in therapy group than in control group. The 6,12 months survival rates were 92.0%, 48.6% in therapy group and 62.9%, 34.3% in control group. The adverse effect such as fever,nausea,vomiting and leukopenia occurred in both groups, but there were no significant diffevence in two groups. Conclusions The treatment to use interleukin-2 and cisplatine through thoracic tube is regarded as effective,slight side-effect and well tolerated method for malignant pleural effusion.
出处
《国际呼吸杂志》
2009年第11期669-671,共3页
International Journal of Respiration
关键词
顺铂
白介素2
恶性胸腔积液
Cisplatine
Interleukin-2
Malignant pleural effusion
